Medical News

RSS

Valeant third quarter revenue decreases 2% to $208.3 million

Valeant Pharmaceuticals International, Inc. announces third quarter financial results for 2010. The merger of Biovail Corporation and Valeant Pharmaceuticals International was completed on September 28, 2010.

4 Nov 2010

Undamaged portions of brain 'take over' and support recovery of function: Study

New research provides fascinating insight into mechanisms that underlie recovery after damage to a region of the brain important for memory and attention. The research, published by Cell Press in the November 4th issue of the journal Neuron, highlights the role of undamaged portions of the brain that can "take over" and support the recovery of function.

4 Nov 2010

NWBT receives $490,000 in two grants under QTDP program

Northwest Biotherapeutics today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants.

4 Nov 2010

SXC Health third quarter revenue increases 28% to $106.4 million

SXC Health Solutions Corp. announces its financial results for the three-month and nine-month periods ended September 30, 2010. Financial references are in U.S. dollars unless otherwise indicated.

4 Nov 2010

Viking Systems third quarter sales decreases 8% to $1,832,502

Viking Systems, Inc. today announced financial results for its third quarter ended September 30, 2010. The Company reported a net loss for the quarter ended September 30, 2010 of $632,565 or $0.01 per share and net loss of $1,378,865 or $0.03 per share for the nine months ended September 30, 2010.

4 Nov 2010

Achillion receives $2.0 million in eight federal grants under QTDP program

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that is has been awarded approximately $2.0 million in eight federal grants under the Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

Orchid third quarter revenue increases 18% to $17.3 million

Orchid Cellmark Inc. a leading international provider of identity DNA testing services, today reported revenues increased 18% to $17.3 million for the third quarter 2010, as compared to $14.7 million in the third quarter 2009. Gross margin increased to 38% and operating income in the quarter was $141 thousand.

4 Nov 2010

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.

4 Nov 2010

Testosterone treatment for frailty in older men lacks long term benefits

The beneficial effects of six months of testosterone treatment on muscle mass, strength and quality of life in frail elderly men are not maintained at six months post-treatment, according to a study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

4 Nov 2010

Interventional Spine receives U.S. patent for Spinal Fixation

Interventional Spine, Inc. today announced that the United States Patent Office has issued U.S. Patent No. 7,824,429, entitled Method and Apparatus for Spinal Fixation.

4 Nov 2010

CombiMatrix receives $488,958 grant under QTDP program

CombiMatrix Corporation a molecular diagnostics company with a focus on DNA-based clinical diagnostic testing services for oncology and pre-and postnatal developmental disorders, announced today the award of $488,958 under the Internal Revenue Service's Section 48D for Qualifying Therapeutic Discovery Projects.

4 Nov 2010

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments.

4 Nov 2010

Prestige Brands second fiscal quarter net revenue decreases 3% to $78.3 million

Prestige Brands Holdings, Inc. today announced results for the second quarter and first half of fiscal year 2011, which ended on September 30, 2010. The Company also announced the completion on November 1, 2010 of the acquisition of Blacksmith Brands, Inc., which added five over-the-counter healthcare products to its business.

4 Nov 2010

Antigenics awarded $424,720 grant under QTDP program

Antigenics Inc. today announced that it has been awarded $424,720 in grants under the IRS' Qualifying Therapeutic Discovery Project (QTDP) program. The grants were awarded in recognition of our two qualifying programs: AG-707, a phase 1 therapeutic vaccine for the treatment of genital herpes and QS-21 Stimulon® adjuvant.

4 Nov 2010

Valeant's board approves $1.5 billion securities repurchase program

Valeant Pharmaceuticals International, Inc. today announced that it may make purchases of its convertible notes, senior notes and/or common shares under a $1.5 billion securities repurchase program (collectively, the "Securities Repurchase Program") approved by Valeant's Board of Directors.

4 Nov 2010

Novel serum test may help diagnose early pregnancy location and outcome

Researchers may have identified a promising novel diagnostic biomarker for ectopic pregnancy, according to a study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). In the western world, deaths from ectopic pregnancy are not common but in the developing world one in ten women who are admitted with an ectopic pregnancy die.

4 Nov 2010

PDI announces acquisition of Group DCA

PDI, Inc., a leading provider of integrated promotional outsource services to health care companies, today announced the expansion of its business with the acquisition of Group DCA, a privately held interactive digital communications agency serving biopharmaceutical companies. Excluding transaction costs, PDI expects the acquisition to be cash flow positive immediately and accretive to earnings in 2011.

4 Nov 2010

Inspire third quarter net loss decreases to $7.6 million

Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2010, reporting a net loss of $7.6 million or ($0.09) per share, an improvement from the third quarter of 2009 during which the Company incurred a net loss of $8.5 million or ($0.12) per share.

4 Nov 2010

Most kidney care providers opt to participate in new Medicare 'bundled' payment system: Study

The Kidney Care Council (KCC), a nonprofit national health care association composed of leading kidney dialysis provider companies who care for a majority of ESRD patients nationwide, released new data today revealing that 98 percent of kidney care providers participating in a recent study have opted to participate in the new Medicare "bundled" payment system in January 2011, more than twice the rate originally anticipated.

4 Nov 2010

Benchmark adds Class III medical device manufacturing capabilities in Thailand

Benchmark Electronics, Inc., a leading integrated electronics manufacturing services (EMS) provider, announced its Thailand facility has successfully completed a full Quality System Inspection Technique (QSIT) audit from the Food and Drug Administration (FDA), through its premarket approval (PMA) supplement evaluation process, to manufacture Class III finished devices on behalf of large tier-one medical original equipment manufacturers (OEMs).

4 Nov 2010